Pier Paolo Claudio, M.D., Ph.D. shares ChemoID results with prominent scientists

Pier Paolo Claudio, M.D., Ph.D. (Marshall University Graduate Faculty, Cancer Biology research cluster), was an invited speaker at the prestigious Cancer Stem Cell Conference at Case Western University in August. Claudio traveled to Cleveland, OH to provide the ChemoID clinical trial data for the Central Nervous System (CNS) tumor series in a presentation titled: Chemosensitivity Assay for Targeting Cancer Stem-Like Cells in Malignant Brain Tumors. His work was well-received by the 500 world-renowned, national, and international cancer scientists who attended the conference. The opportunity to present his results was “extremely rewarding,” said Claudio.

ChemoID is the result of Claudio’s focus on translational research which is aimed at taking laboratory discoveries to a patient’s bedside. He and his collaborators have developed a method of forecasting the efficacy of particular chemotherapy drugs on specific individuals diagnosed with certain types of cancers. This tool for choosing the best personalized therapy for cancers such as brain, lung, or breast, in addition to others, has shown very positive results in the clinical trials leading to hospital use of the technology.

ClaudioOn October 15, the Edwards Comprehensive Cancer Center will implement ChemoID. Additionally, transportation stability studies have shown that national and international samples can be safely sent to Claudio’s lab paving the way for broad use of this method.

Claudio noted that, “among all the talks presented at the meeting, we were one of the few institutions presenting an actual completed clinical trial with promising results. This certainly increased our national exposure and the number of collaborations with other leading institutions in the field.”

Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy

HUNTINGTON, W.Va. – Dr. Pier Paolo Claudio, a researcher at the Marshall University Joan C. Edwards School of Medicine, is traveling to Paphos, Cyprus, next month to present his work to personalize chemotherapy for cancer treatment.

Claudio was invited to give the talk at the 5th International Conference on Recent Advances in Health and Medical Sciences, which will be held July 6-12.

He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients’ tumors to chemotherapy treatment for lung, brain/spine and breast cancer.

He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.

Claudio“Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient,” says Claudio. “The basic problem is that patients with similar diagnoses don’t always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient—giving them an edge in the fight against cancer.”

He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient’s cancer—increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.

In addition to presenting his own research at the conference, Claudio will be moderating a session, “Advances in Oncology and Anticancer Research. Cancer Pathology.”

Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.

###

Contact:  Ginny Painter, Communications Director, Marshall University Research Corporation, 304-746-1964 (o) www.marshall.edu/murc